Tech Company Financing Transactions

DNAtriX Funding Round

DNAtriX closed a $20 million Series B financing round on 10/14/2014. Backers included Morningside Group, Mercury Fund and Targeted Technology Fund.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

2450 Holcombe Blvd. X 200
Houston, TX 77021
USA

Phone

(832) 930-2401

Website

www.dnatrix.com

Email Address

[email protected]

Overview

DNAtrix is a clinical stage, biotechnology company developing virus-driven immunotherapies for cancer. DNAtrix s lead product, DNX-2401, is a modified common cold virus that targets and kills cancer cells selectively.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Frank Tufaro

        

Chief Financial Officer

Brian Mooney

        

VP - Bus. Development

Brett Ewald

        

VP - Manufacturing

Erin Mitchell

        

VP - R & D

Karen Gammon

        

VP - R & D

Imre Kovesdi

        

VP - R & D

Joan Robbins

        

Browse more venture capital transactions:

Prev: 10/14/2014: Wireless Seismic venture capital transaction
Next: 10/14/2014: Columbia Green Technologies venture capital transaction

Share this article

About Database of VC Transactions

Our team works diligently to report on funding rounds that are announced publicly. VC investment data records on this site are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary